Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study aims at evaluating efficacy and safety of Symbicort® Turbuhaler® in Chinese COPD
patients as defined by GOLD treatment guidelines in order to obtain an approval for
indication of COPD from Chinese State Food and Drug Administration.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate Terbutaline